Evidence-based treatment for a patient with advanced rectal cancer with BRAF V600E mutation / 肿瘤

ABSTRACT

Objective: Based on evidence-based clinical evidence, an appropriate individualized treatment strategy was established for one patient with V-raf murine sarcomarosoncovirus oncogene homologous B (BRAF) V600E-mutant recurrent metastatic rectal cancer after chemotherapy. Methods: After evaluating the case data completely, the treatmentrelated clinical problems were put forward. Cochrance Library, PubMed, CBM (SinoMed), Embase, Chinese Journal Full-Text Database and Wanfang database were retrieved by computer to find the randomized controlled trial, systematic review and Meta-analysis about metastatic rectal cancer with BRAF V600E mutation. The 2001 Oxford Centre for Evidence-based Medicine Levels of Evidence was used to grade the literatures. Results: A total of 14 relevant studies were retrieved, most of which were grade A evidence, with high evidence intensity and reliable conclusion. Based on evidence-based clinical evidence, a suitable individualized treatment strategy was established for this patient, which was antiepidermal growth factor receptor (EGFR) antibody combined with BRAF inhibitor treatment. The short-term incidence rate of adverse reactions was low, the clinical symptoms were well controlled, and the result of response evaluation was partial response. Conclusion: Based on evidence-based clinical evidence, a reasonable treatment plan for patients with BRAF V600E-mutant metastatic colorectal cancer can effectively improve the therapeutic effect and prognosis.